US5143731A — Body cavity drug delivery with thermo-irreversibl…

Claim 1

Independent Claim 269 words

A process for treating a condition requiring pharmacological treatment, which comprises administering to a body cavity of a mammal requiring pharmacological treatment a composition comprising a hyperosmotic, isoosmotic, or hypoosmotic aqueous gel having a buffered pH, which is a liquid at room temperature or below and a thermoreversible gel at mammalian body temperature, said aqueous gel comprising an ionic polysaccharide and (A) a polyoxyalkylene block copolymer of the formula Y[(A).sub.n --E--H].sub.x (I) wherein A is a polyoxyalkylene moiety having an oxygen/carbon atom ratio of less than 0.5, x is at least 1, Y is derived from water or an organic compound containing x reactive hydrogen atoms, E is a polyoxyethylene moiety, n has a value such that the average molecular weight of A is at least about 500 to about 900, as determined by the hydroxyl number of an intermediate, Y[(A).sub.n --H].sub.x (II) and wherein the total average molecular weight of the copolymer is at least about 5000, (B) a pharmacologically effective amount of a drug selected from the group consisting of antibacterials, antihistamines and decongestants, antiinflammatories, antiparasitics, antivirals, local anesthetics, antifungals, amebedicals, trichomonocidals, analgesics, antiarthritics, antiasthmatics, anticoagulants, anticonvulsants, antidepressants, antidiabetics, antineoplastics, antipsychotics, antihypertensives, antiprotozoals, spermicidals, and muscle relaxants, and (C) a pharmaceutically acceptable buffer sufficient to maintain the pH of said aqueous composition at a desired level, and, optionally, a latent form of a counter-ion capable of thermoirreversibly gelling said composition wherein said composition contains about 0.01% to about 60% by weight of said drug, about 10 to about 50% by weight of said polyoxyalkylene polymer, and about 0.2 to about 2.5% by weight of said ionic polysaccharide.

Claim 2

Dependent Claim 269 words

A process for treating a condition requiring pharmacological treatment, which comprises administering to a body cavity of a mammal requiring pharmacological treatment a composition comprising a hyperosmotic, isoosmotic, or hypoosmotic aqueous gel having a buffered pH, which is a liquid at room temperature or below and a thermoreversible gel at mammalian body temperature, said aqueous gel comprising an ionic polysaccharide and (A) a polyoxyalkylene block copolymer of the formula Y[(A).sub.n --E--H].sub.x (I) wherein A is a polyoxyalkylene moiety having an oxygen/carbon atom ratio of less than 0.5, x is at least 1, Y is derived from water or an organic compound containing x reactive hydrogen atoms, E is a polyoxyethylene moiety, n has a value such that the average molecular weight of A is at least about 500 to about 900, as determined by the hydroxyl number of an intermediate, Y[(A).sub.n --H].sub.x (II) and wherein the total average molecular weight of the copolymer is at least about 5000, (B) a pharmacologically effective amount of a drug selected from the group consisting of antibacterials, antihistamines and decongestants, antiinflammatories, antiparasitics, antivirals, local anesthetics, antifungals, amebedicals, trichomonocidals, analgesics, antiarthritics, antiasthmatics, anticoagulants, anticonvulsants, antidepressants, antidiabetics, antineoplastics, antipsychotics, antihypertensives, antiprotozoals, spermicidals, and muscle relaxants, and (C) a pharmaceutically acceptable buffer sufficient to maintain the pH of said aqueous composition at a desired level, and, optionally, a latent form of a counter-ion capable of thermoirreversibly gelling said composition wherein said composition contains about 0.01% to about 60% by weight of said drug, about 10 to about 50% by weight of said polyoxyalkylene polymer, and about 0.2 to about 2.5% by weight of said ionic polysaccharide.

Claim 3

Dependent Claim 67 words

The process of claim 1 wherein Y in said formulas I and II is a water soluble organic compound having 1-6 carbon atoms, and said copolymer is selected from the group consisting of a polyoxyethylene-polyoxybutylene block copolymer, a polyoxyethylene-polyoxypropylene block copolymer and mixtures thereof, and wherein the polyoxyethylene moiety constitutes at least 70% by weight of the copolymer and wherein the pH is maintained at about 7.4±0.2.

Claim 4

Dependent Claim 32 words

The process of claim 2, wherein said copolymer is selected from block copolymers which form aqueous gels at a concentration of about 10-40% by weight of the total weight of said composition.

Claim 5

Dependent Claim 26 words

The process of claim 3, wherein said Y is a compound selected from the group consisting of propylene glycol, glycerin, pentaerythritol, trimethylolpropane, ethylenediamine, and mixtures thereof.

Claim 6

Dependent Claim 35 words

The process of claim 4, wherein Y is derived from propylene glycol, A is the residue of propylene oxide, and the intermediate of Formula II has an average molecular weight of at least about 900.

Claim 7

Dependent Claim 35 words

The process of claim 5, wherein Y is derived from butylene glycol, A is the residue of butylene oxide, and the intermediate of Formula II has an average molecular weight of at least about 500.

Claim 8

Dependent Claim 200 words

The process of claim 6, wherein said copolymer has the formula HO(C.sub.2 H.sub.4 O).sub.b (C.sub.4 H.sub.8 O).sub.a (C.sub.2 H.sub.4 O).sub.b H (III) wherein in III, a and b are integers such that the hydrophobe base represented by (C 4 H 8 O) a has a molecular weight of at least 1000, as determined by hydroxyl number, the polyoxyethylene chain constitutes at least about 60% by weight of the copolymer, and the copolymer has a total average molecular weight of at least 5,000, or HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b H (IV) wherein in IV, a and b are integers such that the hydrophobe base represented by (C 3 H 6 O) has a molecular weight of at least about 1500 average molecular weight, as determined by hydroxyl number, the polyoxyethylene chain constitutes at least about 60% by weight of the copolymer, and the copolymer has a total average molecular weight of at least 5,000, or ##STR3## wherein in V, a and b are integers such that the copolymer has a hydrophobe molecular weight of at least about 2000, a hydrophile content of at least about 60%, and a total average molecular weight of at least about 5,000.

Claim 9

Dependent Claim 10 words

The process of claim 7 wherein said copolymer is ##STR4##

Claim 10

Dependent Claim 59 words

The process of claim 8, wherein said counter-ion is selected from the group consisting of at least one of calcium, strontium, and aluminum, said ionic polysaccharide is selected from the group consisting of an ammonium alginate, an alkali metal alginate, and mixtures thereof, and said counter-ion is present as a microencapsulated component or incorporated with an ion exchange resin.

Claim 11

Dependent Claim 53 words

The process of claim 8, wherein said counter-ion is the anion of an ammonium or metal salt, said anion is selected from the group consisting of the phosphates, metaphosphates, pyrophosphates and tripolyphosphates, said ionic polysaccharide is chitosan, and said counter-ion is present as a microencapsulated component or incorporated with an ion exchange resin.

Claim 12

Dependent Claim 315 words

A process for treating a condition requiring pharmacological treatment or the administration of a diagnostic agent which comprises administering to a body cavity of a mammal a composition comprising a hyperosmotic, isoosmotic, or hypoosmotic aqueous gel, having a buffered pH, said aqueous gel comprising an ionic polysaccharide, a surfactant, and a polyoxyalkylene polyether having a molecular weight of about 10,000 to about 100,000 which is selected from the group consisting of (A) polyoxyalkylene polyethers prepared by reacting ethylene oxide and at least one lower alkylene oxide having 3 to 4 carbon atoms with at least one active hydrogen-containing compound having from 3 to 10 carbon atoms and from 3 to 6 active hydrogens to prepare a heteric or block copolymer intermediate and further reacting said copolymer intermediate with at least one alpha-olefin oxide having an average carbon chain length of about 20 to about 45 aliphatic carbon atoms, and wherein said alpha-olefin oxide is present in the amount of about 0.3 to 10 percent by weight based upon the total weight of said polyether and (B) polyoxyalkylene polyethers prepared by reacting ethylene oxide with at least one active hydrogen-containing compound having from 2 to 10 carbon atoms and from 2 to 6 active hydrogens to prepare a homopolymer intermediate and further reacting said homopolymer with at least one alpha-olefin oxide having an average carbon chain length of about 20 to 45 aliphatic carbon atoms and wherein said alpha-olefin oxide is present in the amount of about 0.3 to 10 percent by weight based on the total weight of said polyether, and, optionally, a latent form of a counter-ion capable of cross-linking the ionic polysaccharide wherein said composition contains about 0.01% to about 60% by weight of said drug, up to 10% by weight of a combination of said surfactant and said polyoxyalkylene polyether, and about 0.2 to about 2.5% by weight of said ionic polysaccharide.

Claim 13

Dependent Claim 315 words

A process for treating a condition requiring pharmacological treatment or the administration of a diagnostic agent which comprises administering to a body cavity of a mammal a composition comprising a hyperosmotic, isoosmotic, or hypoosmotic aqueous gel, having a buffered pH, said aqueous gel comprising an ionic polysaccharide, a surfactant, and a polyoxyalkylene polyether having a molecular weight of about 10,000 to about 100,000 which is selected from the group consisting of (A) polyoxyalkylene polyethers prepared by reacting ethylene oxide and at least one lower alkylene oxide having 3 to 4 carbon atoms with at least one active hydrogen-containing compound having from 3 to 10 carbon atoms and from 3 to 6 active hydrogens to prepare a heteric or block copolymer intermediate and further reacting said copolymer intermediate with at least one alpha-olefin oxide having an average carbon chain length of about 20 to about 45 aliphatic carbon atoms, and wherein said alpha-olefin oxide is present in the amount of about 0.3 to 10 percent by weight based upon the total weight of said polyether and (B) polyoxyalkylene polyethers prepared by reacting ethylene oxide with at least one active hydrogen-containing compound having from 2 to 10 carbon atoms and from 2 to 6 active hydrogens to prepare a homopolymer intermediate and further reacting said homopolymer with at least one alpha-olefin oxide having an average carbon chain length of about 20 to 45 aliphatic carbon atoms and wherein said alpha-olefin oxide is present in the amount of about 0.3 to 10 percent by weight based on the total weight of said polyether, and, optionally, a latent form of a counter-ion capable of cross-linking the ionic polysaccharide wherein said composition contains about 0.01% to about 60% by weight of said drug, up to 10% by weight of a combination of said surfactant and said polyoxyalkylene polyether, and about 0.2 to about 2.5% by weight of said ionic polysaccharide.

Claim 14

Dependent Claim 23 words

The process of claim 11, wherein said polyether is prepared using a heteric copolymer intermediate and wherein the pH is maintained at 7.4±0.2.

Claim 15

Dependent Claim 44 words

The process of claim 12, wherein said polyether is prepared using an alpha-olefin oxide having an average carbon chain length of about 20 to 30 carbon atoms, present in the amount of about 0.3 to 10 percent of the total weight of said polyether.

Claim 16

Dependent Claim 51 words

The process of claim 13, wherein said polyether contains a proportion of ethylene oxide residue to the residue of said lower alkylene oxide of about 70 to about 90 percent by weight of ethylene oxide residue to about 30 to about 10 percent by weight of said lower alkylene oxide residue.

Claim 17

Dependent Claim 18 words

The process of claim 14, wherein said polyether is prepared using propylene oxide as the lower alkylene oxide.

Claim 18

Dependent Claim 15 words

The process of claim 15, wherein said polyether is prepared using a block copolymer intermediate.

Claim 19

Dependent Claim 44 words

The process of claim 16, wherein said polyether is prepared using an alpha-olefin oxide having an average carbon chain length of about 20 to 30 carbon atoms, present in the amount of about 0.3 to 10 percent of the total weight of said polyether.

Claim 20

Dependent Claim 54 words

The process of claim 17, wherein said polyether is prepared using a proportion of ethylene oxide residue to the residue of said lower alkylene oxide of from about 70 to about 90 percent by weight of ethylene oxide residue to about 30 to about 10 percent by weight of said lower alkylene oxide residue.

Claim 21

Dependent Claim 17 words

The process of claim 18, wherein said polyether is prepared using propylene oxide as the alkylene oxide.

Claim 22

Dependent Claim 14 words

The process of claim 11, wherein said polyether is polyether (B) of claim 11.

Claim 23

Dependent Claim 96 words

The process of claim 20, wherein said polyether is prepared using an alpha-olefin oxide having an average carbon chain length of about 20 to 30 carbon atoms, present in the amount of about 0.3 to 10 percent of the total weight of said polyether, said counter-ion is selected from the group consisting of at least one of calcium, strontium, and aluminum, and said ionic polysaccharide is selected from the group consisting of an ammonium alginate, an alkali metal alginate, and mixtures thereof and is present as a microencapsulated component or incorporated with an ion exchange resin.

Claim 24

Dependent Claim 92 words

The process of claim 20, wherein said polyether is prepared using an alpha-olefin oxide having an average carbon chain length of about 20 to 30 carbon atoms, present in the amount of about 0.3 to 10 percent of the total weight of said polyether, said counter-ion is the anion of an ammonium or metal salt, said anion is selected from the group consisting of the phosphates, metaphosphates, pyrophosphates, tripolyphosphates, and mixtures thereof and said ionic polysaccharide is chitosan which is present as a microencapsulated component or incorporated with an ion exchange resin.

Annuity Stage	Window Opens	Payment Deadline	Surcharge Period Until	Estimated Fee	Status
3.5 Years (Year 4)	1995-09-01	1996-03-02	1996-09-01	$2000.00	Window Closed / Lapsed
7.5 Years (Year 8)	1999-09-01	2000-03-02	2000-09-01	$3760.00	Window Closed / Lapsed
11.5 Years (Year 12)	2003-09-01	2004-03-02	2004-09-01	$7700.00	Window Closed / Lapsed

Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels

Abstract

Inventors

Bibliographic Details

Claims Analysis

References Cited (Backward Citations)

USPTO Annuity & Maintenance Windows

Assigned Categories & Tags

Assign Category Tag